San Antonio Breast Cancer Symposium | Conference

Axillary Radiotherapy Alternative to Lymph Node Dissection in Early-Stage Breast Cancer

December 7th 2018

Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.

Accelerated PBI Not Equal to WBI in Ipsilateral Breast Tumor Recurrence

December 7th 2018

Accelerated partial breast irradiation following lumpectomy was marginally not found to be equivalent to whole breast irradiation to control ipsilateral breast tumor recurrence.

Myelopreservation Possible With CDK4/6 Inhibitor Trilaciclib in TNBC

December 7th 2018

A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.

Lower-Dose Tamoxifen Reduces Recurrence Risk, Toxicity Incidence in Breast Cancer

December 7th 2018

The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.

CTC Counts Demonstrate Selection Value in Metastatic Breast Cancer

December 6th 2018

The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Bidard on the Clinical Utility of Circulating Tumor Cell Count in Breast Cancer

December 6th 2018

Francois-Clement Bidard, MD, PhD, professor, medical oncologist, Institut Curie, discusses the clinical utility of circulating tumor cell count (CTC) in breast cancer at the 2018 San Antonio Breast Cancer Symposium.

Dr. Vicini on Partial Breast Irradiation Versus Whole Breast Irradiation in Women With Early-Stage Breast Cancer

December 6th 2018

Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, compares the use of partial breast irradiation (PBI) with that of whole breast irradiation (WBI) in women with early-stage breast cancer at the 2018 San Antonio Breast Cancer Symposium.

PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC

December 6th 2018

Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.

Earlier Adjuvant Chemotherapy Benefits Patients With TNBC

December 6th 2018

Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.

Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBC

December 6th 2018

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.

Dr. Hershman on Adherence to Cardiovascular Medication and Cardiovascular Events in Breast Cancer

December 6th 2018

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the association between cardiovascular medication and cardiovascular events following a diagnosis of early-stage breast cancer during the 2018 San Antonio Breast Cancer Symposium.

Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes

December 6th 2018

Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.

No Survival Benefit With Adjuvant Capecitabine in Early-Stage TNBC

December 6th 2018

Adjuvant treatment with capecitabine in patients with early-stage triple-negative breast cancer did not significantly improve disease-free or overall survival compared with observation, according to results from the phase III GEICAM/CIBOMA trial that were presented at the 2018 San Antonio Breast Cancer Symposium.

T-DM1 Likely New Adjuvant Standard in High-Risk HER2+ Breast Cancer

December 6th 2018

Ado-trastuzumab emtansine reduced the risk of invasive disease recurrence or death by 50% compared with trastuzumab as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy.

Analysis Confirms Safety of Olaparib in Breast Cancer

January 5th 2018

An analysis of the phase III OlympiAD study showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.

Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer

December 14th 2017

The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline BRCA-mutated, HER2-negative metastatic breast cancer,

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

December 9th 2017

The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.

Antibody-Drug Conjugate Active in Heavily Pretreated Metastatic TNBC

December 9th 2017

Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.

Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide

December 9th 2017

Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers

December 9th 2017

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.